Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA)

BackgroundTo assess the efficacy and tolerability of saxagliptin and C-peptide secretion in patients with diagnosed type 2 diabetes classified as glutamic acid decarboxylase antibody (GADA)-positive or GADA-negative. MethodsPost hoc analysis of data pooled from five randomized, placebo-controlled, 24-week phase 3 studies (n=2709) was conducted. We evaluated mean change from baseline at week 24 in HbA(1c), fasting plasma glucose, postprandial plasma glucose, fasting and postprandial C-peptide, and HOMA2-% and the proportion of patients achieving HbA(1c)<7% (53mmol/mol) at week 24. ResultsSaxagliptin produced greater adjusted mean reductions from baseline in HbA(1c)versus placebo for GADA-negative [difference vs placebo (95% CI), -0.62% (-0.71% to -0.54%); -6.8 mmol/mol (-7.8, -5.9)] and GADA-positive patients [-0.64% (-1.01% to -0.27%); -7.0 mmol/mol (-11.0, -3.0)]. Consistently, saxagliptin produced a greater reduction from baseline in fasting plasma glucose and postprandial plasma glucose versus placebo in GADA-positive versus GADA-negative patients, and more patients achieved HbA(1c)<7% (53mmol/mol) with saxagliptin versus placebo in both GADA-negative and GADA-positive patients. Saxagliptin increased -cell function as assessed by HOMA2-% and postprandial C-peptide area under the curve from baseline in patients in both GADA-positive and GADA-negative patients. Adverse events and hypoglycaemic events were similar across treatment groups and GADA categories. ConclusionSaxagliptin was effective in lowering blood glucose levels and generally well tolerated in GADA-positive patients. Interestingly, saxagliptin appears to improve -cell function in these patients, although a longer treatment duration may be needed to confirm this finding. Copyright (c) 2015 John Wiley & Sons, Ltd.